脂肪肝
脂肪生成
胰岛素抵抗
小檗碱
医学
利拉鲁肽
脂质代谢
肠道菌群
人口
糖尿病
生物信息学
2型糖尿病
疾病
药理学
内科学
生物
作者
Anna Koperska,Agnieszka Wesołek,Małgorzata Moszak,Monika Szulińska
出处
期刊:Nutrients
[MDPI AG]
日期:2022-08-23
卷期号:14 (17): 3459-3459
摘要
The incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) has been rapidly increasing during the last decade. It is a relevant health problem that affects 25% of the general population. NAFLD involves an extensive array of clinical conditions. So far, no approved pharmacological therapy for NAFLD has been developed. Multiple bioactive compounds have been proposed to treat NAFLD. One of the most promising is Berberine (BBR). Its pleiotropic effect positively impacts various cardiometabolic aspects. In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy. BBR ameliorates NAFLD by affecting numerous abnormalities. It inhibits lipogenesis and gluconeogenesis, improves insulin resistance and lipid profile, and modulates gut microbiota. The exact mechanism underlying these effects is not yet entirely explained. A growing amount of evidence confirming the positive effects of BBR on multiple metabolic pathways, such as lipids and glucose metabolism, energy homeostasis, or gut microbiota modulation, allows us to speculate about the importance of this natural bioactive substance for NAFLD therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI